Motorica is now TEHLIN's exclusive India representative for lower-limb prosthetics. A distribution deal is a specific kind of mechanism.

Motorica announced this week that it has become the exclusive India representative for TEHLIN’s lower-limb prosthetic technologies. BW Healthcare World and Pharmabiz.com both covered the announcement on August 13, framing it as a move to expand prosthetics access in one of the world’s largest markets for unmet device need.

That framing is accurate as far as it goes. What it underspecifies is what an exclusive representation agreement actually does — and what it leaves untouched — in a country where the distance between available technology and accessible technology runs through a set of structural problems that distribution deals address unevenly.

What “exclusive representative” means in this context

When a company becomes the exclusive representative or exclusive distributor for a medical device in a foreign market, the arrangement typically covers a defined set of functions — and it is worth being precise about what those are.

Regulatory submission and maintenance. Foreign medical devices entering India require registration with the Central Drugs Standard Control Organisation (CDSCO), which functions as India’s counterpart to the FDA or CE Mark bodies. An exclusive representative is typically the entity responsible for managing that process: assembling the technical dossier, interfacing with the regulator, obtaining and maintaining the import license. Without CDSCO registration, a device cannot legally be sold in India as a medical device. The registration process is not instant — timelines for Class B and C devices can run twelve to twenty-four months — but having a designated Indian entity handling it is materially faster than a foreign manufacturer attempting to navigate it from outside.

Import, logistics, and distribution. The representative manages the supply chain from the manufacturer to the Indian market: freight, customs clearance, warehousing, and in-country distribution to hospitals, rehabilitation centers, clinics, and prosthetists.

Sales and clinical support. Establishing the network of practitioners who can prescribe, fit, and follow up the device. The “exclusive” in exclusive representation means no competing distributor — the partner controls the channel and, by extension, pricing in the domestic market.

What an exclusive representation agreement does not typically cover: changing the manufacturing cost of the underlying device, producing it locally, creating prosthetist training programs, or addressing the workforce and infrastructure constraints that limit who can actually access the device once it clears customs.

The scale of the problem this is entering

India’s lower-limb amputation burden is among the largest in the world, and the prosthetics access infrastructure is not built to match it.

The primary driver is diabetes. India has approximately 77 million people living with diabetes — one of the highest national totals globally — and diabetic peripheral vascular disease is the leading cause of non-traumatic lower-limb amputation in the country. Peripheral neuropathy delays detection of foot wounds; peripheral vascular disease impairs healing; the sequence that ends in below-knee or above-knee amputation is well-documented and, in India, runs at a scale that far exceeds the country’s capacity to fit the people who survive it with working prostheses.

Road traffic injuries are the second major source of lower-limb limb loss. India records among the world’s highest road fatality and severe-injury rates, and traumatic lower-limb loss — particularly among motorcycle riders and pedestrians — adds substantially to the population requiring devices.

Against that demand, the supply side is thin. The number of trained prosthetists is insufficient, their distribution is heavily concentrated in metropolitan centers, and most of the population requiring lower-limb prostheses cannot afford imported options at commercial price points. We have covered how Indian prosthetics R&D has historically approached the design brief differently from Western device manufacturers — specifically, by building for the conditions that most Indian users actually live in, rather than the conditions that most Western clinical settings were designed around. That design history is relevant here because it frames what imported commercial devices are entering: a market where the device most successfully distributed in volume — the Jaipur Foot, fitted to more than 1.3 million people — reached that scale precisely because it was inexpensive enough and purpose-designed enough to be deployed through government and charitable infrastructure without requiring insurance reimbursement.

The structural challenges that distribution doesn’t resolve

The government of India operates the Artificial Limbs Manufacturing Corporation of India (ALIMCO) as the primary channel for subsidized or low-cost device provision. ALIMCO manufactures its own device line domestically and distributes through District Disability Rehabilitation Centres (DDRCs) and periodic government-run camps. It is not a procurement body in the sense that it routinely sources foreign commercial devices; it is a manufacturer. For an imported device to reach patients through subsidized channels, it would typically need to enter government procurement through a separately structured tender or institutional arrangement — which is a different and considerably more involved pathway than establishing commercial distribution.

The private hospital network is a different channel. Urban private hospitals serving patients who can afford imported prosthetics — or whose insurance covers them — represent a more tractable market for foreign commercial devices. India’s private health insurance market has expanded, and some policies cover prosthetics. But the population that reaches private urban hospitals with commercial insurance is a small fraction of the population that needs lower-limb prostheses. It is not nothing, and it is not the access gap that the announcement is implicitly invoking.

The prosthetist supply problem is structural and independent of distribution. Bachelor’s-level programs in prosthetics and orthotics exist at a limited number of Indian institutions; master’s-level training is more limited still; and the practitioners who complete training are not evenly distributed — they concentrate in cities where the clinical volume and pay justify it. A foreign device that reaches a Tier 2 city clinic has limited reach if the clinic lacks a prosthetist trained to fit and adjust it. A distribution deal does not create prosthetists.

What the partnership might realistically move

There are scenarios in which a well-managed exclusive distribution arrangement meaningfully improves access to a specific class of lower-limb device for a specific population in India.

If TEHLIN’s devices include lower-cost options designed for moderate-income purchasers — or if Motorica structures pricing agreements with institutional buyers, such as large rehabilitation hospital networks or state-government procurement bodies — the partnership could translate to devices reaching patients in urban and peri-urban settings who currently have limited access to quality lower-limb prostheses beyond domestic options. The CDSCO pathway, once cleared by a dedicated Indian representative, also makes the devices legally available to prosthetists who might previously have been unable to access them at all.

The announcement does not specify TEHLIN’s device lineup, its target price points for the Indian market, or whether any institutional or government procurement arrangement is part of the deal. It does not describe whether prosthetist training programs are included, which is a practical constraint on the device’s reach regardless of how well the logistics work.

The next useful question

The announcement frames the partnership as an access expansion. Whether it is one depends on the price point and procurement channel — details that typically come after the press release.

If TEHLIN’s lower-limb technologies are priced for the private urban market without a path to institutional procurement or subsidization, the access story is primarily a commercial positioning story in a market where millions of people need devices they cannot afford at any import-cost price. If there is a real path to government or institutional channels — ALIMCO partnership, DDRC supply, state disability program procurement — that would represent a different and more consequential development.

Those details have not been announced. The exclusive representation arrangement is a necessary first step toward making any of that possible. It is not sufficient on its own.

---

Amputee News does not provide individualized medical, legal, or device-fitting advice. Information about prosthetics availability in specific regions, including India, varies by location, provider, and insurance or program status. For access to prosthetics services or government programs in India, contact a certified prosthetist or the relevant state-level disability rehabilitation authority.